Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

ACAT inhibitors claimed by DuPont Merck

April 5, 1996

Pierre Fabre reports hypocholesterolemic organosilanes

April 5, 1996

Vitronectin antagonist from Merck & Co. inhibits bone resorption

April 5, 1996

Cortecs licenses salmon calcitonin to Teva

April 5, 1996

Tsumura Juntendo research into aldose reductase inhibitors

March 15, 1996

AI-401 slated to enter phase II

March 15, 1996

Sankyo reports drugs for diabetes

March 15, 1996

Antidiabetic drugs claimed by Tanabe Seiyaku

March 15, 1996

FDA approves Medtronic's blood processing system

March 15, 1996

New Hemosol division to focus on blood substitutes

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...
Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment
BioWorld Science
Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD)...